AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04940182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo 2 times a day during 14 full days
Study NCT06450054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise in diabetic post-stroke patients
Description: The experimental group's members will use the treadmill for a five-minute warm-up and cool-down. Over 12 weeks, they will attend three 40-minute weekly sessions in groups of two to four. They will then perform aerobic exercise for thirty minutes at a heart rate reserve of 60% to 80%. Those with a low exercise tolerance will first be given small workouts lasting at least ten minutes, interspersed with rest periods until they can perform 30 minutes of exercise. They will progress to longer, continuous workouts punctuated by shorter rest periods as their tolerance to exercise grows. The degree of treadmill training intensity will be adjusted step-by-step according to each person's tolerance, heart rate, blood pressure responses, and perceived effort rate. If they exercise beyond their cardiovascular conditioning zone, participants will be instructed to raise their treadmill speed until they achieve it
Study NCT06450054 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic Exercise in Non diabetic post-stroke patients
Description: Group B will be managed aerobic exercise in non-diabetic post-stroke patients. Participants in the control group will walk outside comfortably while maintaining a heart rate reserve of less than 40%. They will be instructed to reduce their pace until their training zone reaches ≤40% if their heart rate reserve exceeds 40%. If the efficacy is demonstrated, participants in the control group will receive the experimental intervention
Study NCT05113888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi weitong granules(High）
Description: take orally before meals, 1 bag each time, 3 times a day.
Study NCT05113888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qizhi weitong granules(Low）
Description: take orally before meals, 1 bag each time, 3 times a day.
Study NCT05113888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take orally before meals, 1 bag each time, 3 times a day.
Study NCT06392139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific Therapy Program for Personality Disorders
Description: The program was founded in 1999; since then, it has provided a wide range of different treatment interventions (outpatient, inpatient and day care). The interventions are psychoanalytically oriented and specifically for patients with Borderline Personality Disorder. Most of them are in the form of group psychoanalytic psychotherapy. The program consists of two steps: 1) an initial reception outpatient clinic where patients are followed after the referral to the Program, for a period of 6-8 months. This first step consists of monthly psychodynamically oriented sessions, monthly psychiatric appointments and application of psychological assessment instruments. The intervention focuses on crisis management and construction of the treatment plan for every patient. 2) The second step consists of long-term psychodynamic psychotherapy interventions, in combination with psychiatric treatment when it is is needed.
Study NCT06392139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU) Group
Description: The TAU group receives the common practice treatment in the two Specific Outpatient Clinics for BPD patients:~The Outpatient Clinic for Borderline Personality Disorder Patients of the 2nd Psychiatric Clinic at the Medical School of National and Kapodistrian University of Athens called Attikon General University Hospital and The Outpatient Clinic for Borderline Personality Disorder Patients of the Psychiatric Clinic of Sismanogleion General Hospital.~Treatment As Usual (TAU) The TAU includes the psychiatric management, consultation and pharmacotherapy if needed in the two Specific Outpatient Clinics for BPD patients. TAU provides one thirty minutes session per month. In case of crisis management patients contact their psychiatrist during the working hours, or after that they leave a message on the telephone answering machine and if needed make a visit in the Emergency Department of the Hospital on Duty.
Study NCT04736927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: From Day 3 to Day 8, GLPG3667 capsules q.d. orally in fed state.
Study NCT04736927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: On Day 1 and Day 7 as liquid formulation, orally in fed state.
Study NCT06498622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib + Envafolimab
Description: Drug: Envafolimab Envafolimab 300mg IH D1 q3w Other Name: Immunotherapy, Anti-PD-L1 antibody~Drug: Donafenib Donafenib 100mg PO bid Other Name: tyrosine kinase inhibitor, TKI
Study NCT06522555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide
Description: Drug: Polatuzumab vedotin, Zanubrutinib, Lenalidomide and Rituximab (Pola-ZR2)~Induction therapy:~The Pola-ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Polatuzumab vedotin 1.8 mg/kg, day 2 on the 1st cycle and day 1 on the 2nd to 6th cycle; Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Study NCT06522555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zanubrutinib, rituximab and lenalidomide
Description: Drug: Zanubrutinib, Lenalidomide and Rituximab (ZR2)~Induction therapy:~The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles.~Dosage:~Zanubrutinib, 160 mg bid, po, day 1-21; Lenalidomide, 25 mg qd, po, day 2-11; Rituximab, 375 mg/m2, ivgtt, day 1.~Maintenance therapy:~Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days for 2 years.
Study NCT04738617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter and intra-individual variation in acute responses to two different warm-up types
Description: Comparison of the acute effects of two different warm-up protocols on subsequent performance.
Study NCT05546216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of the Effect of Raised Supine Position and Back Support on Back Pain, Anxiety and Comfort Level in Coronary Angiography Patients
Description: The study was conducted between 01 September 2021 and 30 January 2022 as a randomized single-blind interventional study with a pre-test post-test control group. The sample of the study consisted of patients who underwent coronary angiography. Data; The patient information form was collected with the visual analog scale, state anxiety and immobilization comfort scale. Back support was provided to the intervention group with a pillow at the exit of the angiography and the head of the bed was raised 30 degrees. Back pain intensity at 0, 2 and 4 hours, anxiety and comfort level at 0 and 4 hours were measured. The control group was given routine nursing care.
Study NCT04671043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine and glucose
Description: Caffeine and glucose powder dissolved in water
Study NCT04671043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose alone
Description: Glucose powder dissolved in water
Study NCT05002894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates exercises for flexibility and stability
Study NCT05002894 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: medical standard care for fatigue
Description: supplements and medical care
Study NCT05174858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic dressing ETIK COLLAGENE
Description: The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.
Study NCT05174858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator
Description: The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.
Study NCT05179018 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ribosomal p2 Autoantibodies as a Serum marker
Description: Using serum marker
Study NCT06076018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group morphine
Description: Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally, and 120 mcg intrathecal morphine (ITM) will be administered to the morphine group. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
Study NCT06076018 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group placebo
Description: Spinal anesthesia will be applied to patients in a sitting position, with a midline approach, after aseptic conditions have been achieved. A 25 gauge pencil point spinal needle will be placed in the L3-4 or L4-5 space. Upon aspiration of clear cerebrospinal fluid (CSF), 12 mg hyperbaric bupivacaine and 20 mcg fentanyl will be administered intrathecally. the 24th postoperative hour, all patients will be visited in the ward and the QoR-40 (Quality of Recovery-40) patient satisfaction recovery quality scale, scored between 40-200, will be filled out.
Study NCT06085443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear Hygiene
Description: 2 sprays in each ear, every 3 days at home
Study NCT05589155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application
Description: Intervention will be with mobile health application
Study NCT05269875 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACP
Description: The intervention covers a formal ACP discussion, including provision of a holistic approach (physical, psychological, spiritual, social) and includes symptom control and discussion on illness limitations and prognosis, goal assessment and goal adjustment, financial issue, (un)desirable treatments for current and future care, hopes and wishes, and possibility of involvement of a palliative care team.
Study NCT04671043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Artificial sweetener dissolved in water
Study NCT06523881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey)
Description: Sevoflurane (Sevorane® liquid 100%, Abbvie Pharmaceuticals, Istanbul, Turkey) is a medication used during anesthesia. It is administered by inhalation with an anesthesia device.
Study NCT06523881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Propofol-PF® 1% (Polifarma Pharmaceuticals, Tekirdag, Turkey)
Description: Propofol is a drug used during anesthesia. It is administered intravenously using an infusion pump during surgical procedures.
Study NCT05521334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micropulse transscleral cyclophotocoagulation
Description: glaucomatous patients with uncontrolled intraocular pressure (despite maximal tolerated anti-glaucoma medical treatment) were selected for micro-pulse trans-scleral cyclophotocoagulation using an MP3 handpiece with Iridex Cyclo G6 Laser settings (2000mW of 810 nm infrared diode laser set on micro-pulse delivery mode with 31.3 % duty cycle). The laser will be delivered over three quadrants for 90 seconds for each quadrant (total 270 sec) in Zigzag mode sparing the fourth quadrant for either further intervention or a previous surgery performed. Follow up examination (for at least 6 months) will include assessment of IOP in terms of percentage of IOP reduction and sustainability of results, BCVA, and the number of medications post-operatively.
Study NCT05740189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 CryoBalloon 180° Ablation System
Description: The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
Study NCT04798989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY6463
Description: CY6463 Oral Tablet
Study NCT04798989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study NCT06043778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community care for People with Schizophrenia in India (COPSI)
Description: This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
Study NCT06043778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community care for People with Schizophrenia in India (COPSI)
Description: This intervention is designed to promote collaboration between the person with schizophrenia, their caregivers and the treatment team to deliver a flexible, individualized, and needs-based intervention. The COPSI intervention will be delivered by Community Health Officers in three phases: intensive engagement (0-3 months), stabilization phase (4-7 months), and maintenance phase (8-12).
Study NCT06043778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindLAMP Mobile Application
Description: Participants in COPSI plus mindLAMP arm will have access to COPSI and the mindLAMP mobile application. mindLAMP has already been co-developed and culturally adapted by patients, family members, and clinicians at both Indian sites. Materials (articles, videos, web links, audio files, etc.) will be available on-demand and can be accessed by patients at any time. Community Health Officers will also schedule content to specific participants to promote engagement.
Study NCT03606538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 80 mg midomafetamine HCl
Study NCT06124248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE intervention
Description: The RISE intervention: a 15-weeks blended behavioral intervention, where a primary care physiotherapist coaches participants on striking the balance in their 24h activity pattern, with a focus on reducing and interrupting their sedentary time. This will subsequently lead to an increase in physical activity. Next to that, insights into their personal sleep pattern, sleep hygiene rules and advices will be provided.~Primary care physiotherapists coach people with a first-ever stroke in their home setting by using behavior change techniques and the RISE eCoaching system. The RISE eCoaching system consists of 1) an activity monitor, 2) a smartphone application that provides real-time feedback and contains e-learning modules, 3) a monitoring dashboard for the physiotherapist. Participants receive participatory support from someone from their social network (e.g., partner or close friend) who joins them in the intervention.
Study NCT06597617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted physical activity with aerobic training [GEA]
Description: Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on aerobic training. The first 3 sessions will be accompanied, and will take place either by videoconference or face-to-face, depending on the patient's wishes. Thereafter, each 1st session of the following weeks will also be accompanied and carried out either by videoconference or face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) a block of aerobic activity and (iii) a 2-minute cool-down including breathing exercises. Training will take place in 2 phases. The first phase will involve a total of 90 minutes of aerobic training spread over 3 sessions. The second phase will involve a total of 150 minutes of aerobic training over 3 sessions.
Study NCT06597617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted physical activity with strength training [GRM]
Description: Participants will be required to take part in 3 weekly sessions of adapted physical activity for 3 months following bariatric surgery. These sessions (not exceeding 1 hour and 10 minutes) will focus on eccentric training. The first 3 sessions will be accompanied and conducted face-to-face. Thereafter, each 1st session of the following weeks will also be accompanied and carried out face-to-face. The following 2 sessions of the week will be carried out autonomously.~Each session will be organized into (i) a 5-minute cardio-respiratory warm-up and joint mobilization, (ii) muscle-strengthening exercises and (iii) a 2-minute cool-down including breathing exercises. The exercises used will mainly involve the lower limbs. Training will take place in 2 phases. The first phase will involve an exposure/adaptation phase to eccentric training. The second phase will involve a gradual increase in intensity.
Study NCT06596460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TAVI planning CT (adapted)
Description: TAVI planning CT (adapted) to obtain a standard assessment of the Left Ventricular Outflow Tract (LVOT), valve annulus, aortic root, and ascending aorta up to neck branches. There will be no requirement to scan the ilio-femoral arteries as per standard TAVI planning CT
Study NCT06648876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: 10mg qd for 8 days
Study NCT06648876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg qd for 8 days
Study NCT06658405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.
Study NCT06667154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose nivolumab combined with platinum-based doublet chemotherapy
Description: Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3 mg/kg every 21 days for 3 cycles.
Study NCT05854303 — intervention group
Intervention type: BEHAVIORAL
Intervention: Opioid cessation
Description: opioid cessation will occur during pain rehabilitative program over approximately 3 weeks
Study NCT05854303 — intervention group
Intervention type: OTHER
Intervention: No opioid cessation
Description: Subjects will not stop taking opioids
Study NCT05911828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZY19489 + Ferroquine (FQ)
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
Study NCT05911828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ZY19489-FQ combination or placebo orally after a fasting period of at least 10 h.
Study NCT04641962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bocidelpar
Description: Oral
Study NCT04641962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT06665217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy
Description: Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg/kg iv qd d1), Zanubrutinib(160mg po bid d1-21), Lenalidomide(25mg po qd d1-14) and Prednisone(60mg/m2 po qd d1-5) as induction therapy.
Study NCT06667323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated health service delivery for very young adolescent girls
Description: The proposed HPV-VISION intervention will aim to increase girl-centered access to HPV vaccination and other VYA services through an integrated, routine, community-based delivery model that incorporates household mobilization efforts with enhanced service delivery at the health post level.
Study NCT06613854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral semaglutide
Description: Semaglutide Oral Tablets will be introduced to the Oral Semaglutide Arm as per protocol for regular therapy introduction.
Study NCT06613854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: Empagliflozin Oral Tablets will be introduced to the Empagliflozin Arm as per protocol for regular therapy introduction.
Study NCT04737772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Quitline treatment as usual
Description: TAU is state quitline treatment that may include coaching sessions, text messaging and access to the web-based program plus cessation medications and unlimited calls to the QL for support between sessions.
Study NCT06617221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Composite graft plug
Description: after tooth extraction the socket was grafted with a composite graft plug